the expression of all known DNA repair genes upon FM treatment of D05 melanoma cells wildtype for p53 (24) . Besides the well characterized p53 targets ddb2 and xpc, (25) , a strong and robust induction of the translesion polymerase eta (PolH) was observed. PolH plays an important role in tolerating replication blocking DNA lesions by translesion synthesis (TLS) (26) and is also involved in the replication at fragile sites in the absence of exogenous stress (27, 28) . Here we show induction of PolH following treatment with ICL-inducing drugs, which occurs in p53 wt but not p53 mutated tumor cells. It was also observed in nontransformed cells and in a mouse xenograft model in vivo. Furthermore, we show the induction contributes to resistance against all tested ICL drugs: FM, lomustine (CCNU) and the cyclophosphamide analogon mafosfamide (MAF). The protective effect results from involvement of PolH in the repair of DNA damage induced by these drugs. The data provide an example of acquired drug resistance by upregulation of a TLS polymerase. Since upregulation of PolH was found in normal and cancer cells, the data have implications both for cancer cell resistance and protection of the normal tissue.
Material and methods

Cell lines and anticancer drug treatment:
The cell lines used (A375, D03, D05, MCF7, TK6, U87, LN229, U138, T98G, LN18, LN308, LN319, VH10tert) were described previously (23, 25, 29, 30) and grown in RPMI or DMEM medium containing 10% fetal bovine serum (FBS), in 7% CO 2 at 37°C. Fresh blood was obtained from healthy donors obtained from the blood bank of the University Medical Center Mainz. PBLCs were isolated using density centrifugation and Lymphoprep TM (PROGEN Biotechnik GmbH, Heidelberg, Germany) as described (29) . For growth stimulation, lymphocytes were incubated for 24 h in 24-well tissue culture plates containing plastic-bound anti-CD3 (BD PharMingen, Heidelberg, Germany) plus anti-CD28 antibodies (BD PharMingen, Heidelberg, Germany). If not differentially stated, cells were pre-exposed to 10 µM O 6 -benzylguanine (O 6 BG) and one hour later exposed to fotemustine (FM, diethyl1-[3-(2-chloroethyl)-3-described above. Prior to the nuclear staining the "Click it" reaction was performed as proposed in the manufacturers` instructions.
MTT assay: The metabolic activity of FM-treated cells in comparison with untreated cells was determined by MTT assay. 72 h after exposure to the given anticancer drug, the medium was removed and 50 µl MTT solution (5 mg/ml in PBS) and 100 µL non-colored DMEM medium were added. After 3-4 h of incubation, the medium was aspirated. The cells were lyzed and the blue redox product was dissolved by adding 100 µl 0.04 M HCl in isopropanol. The absorption at 570 nm was determined; the 650 nm background absorption was subtracted.
Host Cell reactivation assay:
To induce DNA damage, the firefly luciferase expression vector pGL2-con (Promega) was ex vivo exposed to different doses of FM in TE buffer at room temperature for 12 h. Thereafter the plasmid was purified by phenol/chloroform extraction.
200 ng plasmids (180 ng of modified pGL2-con and 20 ng of the renilla luciferase expression vector pRLEF-1α) were used for transfection (Effectene Transfection Kit, Qiagen). 24 h after DNA transfection, the luciferase activities were measured using Dual-Glo luciferase assay.
Reactivation of the pGL2-con plasmid was measured as activity of the firefly luciferase.
Activity of the renilla luciferase expressed by the co-transfected plasmid pRLEF-1α was used as control for transfection efficiency and subtracted.
BrdU incorporation: Cells were cultured in RPMI (10% FBS) and after exposure to FM, BrdU (10 µM) was added to the medium. 1 h later the incorporation was analyzed by the BrdU Incorporation Kit (Roche Diagnostics). Experiments were repeated at least three times, mean values ± SD are shown and data were statistically analyzed using Student's t test.
ICL repair measured by single cell gel electrophoresis (SCGE, comet assay):
For the modified comet assay (35) cells were treated with 10 μg/ml FM and, after the indicated time periods, trypsinized and washed with ice-cold PBS. Thereafter, cells were irradiated by 8 Gy.
Alkaline cell lysis and electrophoresis was performed as described (36) . The results are expressed as relative tail moment (%) = fluorescence intensity tail (%) x distance head center to tail end.
Results
Expression of PolH upon FM exposure
In melanoma cells, toxicity induced by chloroethylating anticancer drugs like FM depends on the p53 and MGMT status (23, 37) . The melanoma cell line D05 is p53 wildtype (wt) and expresses MGMT, whereas the melanoma cell line D03 is deficient for both proteins (23) . To identify DNA repair genes that contribute to p53-mediated protection against chloroethylating agents, qRT-PCR arrays were conducted, analyzing the expression of 180 DNA repair and DNA repair associated genes. In this screening we observed the induction of the translesion polymerase eta (PolH) in the p53 wt melanoma cell line D05 following FM treatment (data not shown). To verify the induction of PolH upon FM, the time-dependent expression of polH mRNA was examined by endpoint PCR (Fig. 1B) and qRT-PCR (Fig.   1C ). An enhanced expression of polH mRNA was detectable 8 h after treatment and was constantly increasing during the 24 h post-incubation period. Induction of polH mRNA was accompanied by an increase in the level of PolH protein (Fig. 1D) . The increased expression of PolH was observed between 16 and 32 h after exposure and was preceded by nuclear accumulation of p53 (Fig. 1D) . To clarify whether the induction of polH mRNA and protein is the result of promoter activation, cells were treated with the transcription-blocking agent actinomycin D (ActD). Treatment with the inhibitor only slightly reduced the basal level of polH mRNA, but completely prevented the increase of polH mRNA upon FM, suggesting the induction of polH mRNA to be dependent on RNA de novo synthesis (Fig. 1E) .
Impact of p53 and replication arrest on FM-induced PolH induction
Upregulation of polH was previously reported for human fibroblasts upon treatment with ionizing radiation, with p53 being involved (33) . Therefore we analyzed the FM-mediated induction of polH in melanoma cell lines proficient and deficient for p53 (Suppl. Fig. 1A ).
Induction of polH mRNA was only observed in p53 proficient melanoma cell lines (Suppl. Fig. 1B) . We also observed induction of the canonical p53 targets p21, gadd45a and fasR, substantiating the p53 wt status of the melanoma lines (Suppl. 1B). To further investigate the impact of p53 on polH induction, p53 was inhibited by Pthα, which has been shown to inhibit p53-dependent gene transcription (38) . Pretreatment of D05 cells with 10 µg/ml Pthα completely abrogated the induction of PolH upon FM exposure, both on mRNA ( Fig. 2A ) and on protein level (Fig. 2B) , supporting the notion that PolH is transcriptionally regulated by p53. Finally, ChIP experiments showed in vivo binding of p53 protein to the p53 binding site of the polH promoter in D05 cells exposed to FM (Fig. 2C ).
An intriguing question is whether induction of PolH is triggered by FM-induced ICL, by the formation of DNA repair intermediates like DSBs, or DNA replication arrest. To clarify this, the activation of p53 was analyzed via immunodetection of p53 Ser15 (Fig. 2D) , the induction of PolH by qRT-PCR (Fig. 2E) , replication blockage by BrdU-assay (Fig. 2F ) and the formation of DSBs via yH2AX foci (Fig. 2G) . In order to inhibit replication, we used hydroxyurea (HU), a typical DNA replication blocking agent. of p53 and induction of polH mRNA was observed. At early time points p53 activation and polH induction was more pronounced in the HU exposed cells, reaching its maximum already 2 h after treatment ( Fig. 2D/E ). Upon FM, p53 activation and polH induction was observed starting 8 h post-exposure. Measurement of cell proliferation showed a strong replication arrest between 2 and 16 h following HU, whereas upon FM exposure replication decreased at late times, i.e. between 12 and 16h (Fig. 2F) . Concomitant with the activation of p53, formation of DSBs was detected following FM treatment (Fig. 2G , Suppl. 1D/E).
Upon HU, no DSBs were observed 2-8 h after treatment although a strong pan-staining of yH2AX was detected (data not shown), indicating the replication arrest triggered activation of the DNA damage response (DDR) and, concomitantly, induced polH. However, following FM, which only modestly induced replication arrest in the dose range used, the formation of DSBs seems to play a predominant role in activating the DDR and thereby the induction of polH. Since neither p53 activation nor polH induction was observed at early time points following FM, we conclude that the mono-adducts formed by the agent do not activate the DDR and induce polH.
Induction of PolH in tumor cells, melanoma xenografts and non-transformed cells
To analyze whether the induction of PolH is restricted to melanoma cells or is a common response of tumor cells to crosslinking anticancer drugs, different cell systems were analyzed concerning the inducibility of PolH. In U87 glioma cells, a time-dependent induction of polH mRNA (Fig. 3A , B) and PolH protein ( PolH induction is not a tumor-specific trait, it was also found in non-transformed cells like human diploid fibroblasts (VH10tert) ( (Fig. 4E ). The lack of induction of polH in non-proliferating PBLCs, along with lack of p53 activation ( Fig. 4F ), supports the view that not the primary DNA damage, but replication associated lesions (DSBs) trigger the response.
Impact of PolH on the sensitivity to chloroethylating anticancer drugs
PolH was related to both, resistance and sensitivity to genotoxic stress. Thus PolH deficiency renders human fibroblasts sensitive to UV light, but resistant to ionizing radiation 
Impact of PolH on the repair of FM-induced DNA damage
Next we analyzed whether PolH is involved in the repair of FM-induced DNA damage.
Therefore, host reactivation assays were performed, transfecting ex vivo FM-exposed pGL2-con plasmids into D05 cells. Following dose finding experiments (Suppl. Fig. 1F ), pGL2-con plasmids alkylated with 5 and 25 µg/ml FM were transfected either in polH siRNAtransfected, non-silencing (ns) siRNA-transfected or non-transfected cells and reactivation of the plasmid was determined 24 h later. The data clearly show that knockdown of PolH negatively impacts the ability of cells to reactivate the plasmid (Fig. 6A) , indicating its involvement in the repair of chloroethylating agent-induced DNA damage. Besides performing host cell reactivation assays, we also analyzed the formation and repair of FMinduced DNA damage in vivo. Therefore, the modified alkaline comet assay was used to monitor the repair of DNA crosslinks. The data show that PolH is not involved in the early step of ICL repair since its knockdown does not impact ICL formation or its resolution ( FM-induced block to replication (Fig. 6C) and, in parallel, increased the amount of γH2AX foci (Fig. 6D) . Whereas the amount of γH2AX foci per cell was <3 in untreated cells, FM (10 µg/ml) induced ~40 γH2AX foci per cell 24 h after exposure (Fig. 6D) . Upon siRNA mediated knockdown of PolH, the number of γH2AX foci was significantly enhanced 48 and 72 h after FM in comparison to ns-siRNA transfected cells (Fig. 6D) . We should note that only a subfraction of cells showed γH2AX foci. Therefore, only cells showing >3 foci per cell were included in the quantification. Also, the percentage of cells showing >3 γH2AX foci upon FMexposure was higher in PolH siRNA-transfected cells (Suppl. Fig. 1G ). The finding that only a sub-population of cells showed γH2AX foci indicates that its formation is associated with replication. This is supported by EdU labeling experiments. Formation of γH2AX foci was observed predominantly in replicating cells (Suppl. Fig. 2A ); 24 h after FM exposure more than 85% of cells positive for EdU showed γH2AX foci (Suppl. Fig. 2B ), indicating that DSB formation following FM is restricted to S-phase cells.
To further prove that PolH is involved in the replication-associated repair of chloroethylating agent-induced DNA damage, notably ICL, the cellular localization of PolH was analyzed.
Enhanced nuclear expression of PolH was observed in FM-exposed cells (Suppl. Fig. 2C ). In experiments, in which strong washing conditions were applied to remove non DNA-bound proteins (39), PolH was not detectable in untreated cells (Fig. 6E) . In FM-treated cells, however, a strong staining of PolH was observed in 20 -30% of the cells. Parallel detection of EdU incorporation showed that binding of PolH to the DNA in FM-treated cells occurs predominantly (>80%) in replicating (S-phase) cells (Fig. 6E and Suppl. Fig. 2B ).
Discussion
In glioblastoma and melanoma cells, p53 is one of the major factors influencing toxicity of anticancer drugs. In case of the chloroethylating agents ACNU (22) and FM (25) , this protective effect was related to the induction of the nucleotide excision repair genes xpc and ddb2, which are robustly regulated by p53. To identify additional factors involved in p53- Expression of PolH and p53 protein was analyzed by specific antibodies in whole-cell and nuclear extracts, respectively. ß-Actin was used as loading control. (E) D05 cells were exposed to 10 µg/ml FM in the presence or absence of 1 µM actinomycin D (ActD) and expression of polH mRNA was analyzed by endpoint PCR. 
